Increased tissue levels of omega-3 polyunsaturated fatty acids prevents pathological preterm birth

Aki Yamashita1, Kei Kawana, Kensuke Tomio

  • 1Department of Obstetrics and Gynecology, Faculty of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.

Scientific Reports
|November 2, 2013
PubMed

Insights

Omega-3 fatty acids, like eicosapentaenoic acid (EPA), reduce preterm birth by decreasing inflammation. Resolvin E3 (RvE3), derived from EPA, shows potential as a new therapeutic to prevent preterm birth.

Area of Science:

  • Reproductive biology
  • Inflammation research
  • Nutritional science

Background:

  • Preterm birth is a significant obstetric complication often linked to inflammation.
  • Omega-3 polyunsaturated fatty acids (PUFAs) possess known anti-inflammatory properties.

Purpose of the Study:

  • To investigate the role of omega-3 fatty acids in preventing lipopolysaccharide (LPS)-induced preterm birth.
  • To explore the potential of resolvin E3 (RvE3) as a therapeutic agent for preterm birth prevention.

Main Methods:

  • Utilized fat-1 transgenic mice, which convert omega-6 to omega-3 fatty acids, to study preterm birth incidence.
  • Analyzed uterine gene expression (IL-6, IL-1β) and cervical macrophage infiltration.
  • Performed lipid metabolomics to identify key metabolites, including 18-hydroxyeicosapentaenoate and RvE3.
  • Administered RvE3 to LPS-exposed pregnant wild-type mice to assess its efficacy.

Main Results:

  • Abundance of omega-3 fatty acids in fat-1 mice reduced LPS-induced preterm birth.
  • Fat-1 mice exhibited decreased uterine IL-6 and IL-1β gene expression and fewer cervical macrophages.
  • Elevated levels of 18-hydroxyeicosapentaenoate, metabolized to RvE3, were observed in fat-1 mice.
  • RvE3 administration significantly lowered preterm birth incidence in LPS-exposed wild-type mice.

Conclusions:

  • Increased omega-3 fatty acid levels can mitigate inflammation-driven preterm birth.
  • Resolvin E3 (RvE3) is identified as a key anti-inflammatory metabolite derived from eicosapentaenoic acid (EPA).
  • RvE3 demonstrates therapeutic potential for preventing preterm birth.

Related Concept Videos

Development of the Oral Microbiota01:28

Development of the Oral Microbiota

The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
75
Environmental Influences on Intelligence01:29

Environmental Influences on Intelligence

Despite the strong genetic influence on traits like intelligence, environmental factors significantly shape outcomes. For example, while over 90% of height variation is due to genetic differences, environmental factors such as nutrition also have a notable impact. Similarly, for intelligence, changes in a child's surroundings can significantly alter their IQ. Research shows that enriched environments boost children's academic success and help them develop key cognitive skills. Children...
1.2K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.2K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
747